Preclinical toxicokinetic evaluation of Phortress [2-(4-amino-3- methylphenyl)-5-fluorobenzothiazole lysylamide dihydrochloride] in two rodent species

Pharmacology

Volumn 83, Issue 2, 2009, Pages 99-109

  Bradshaw, T D ^a   Wren, J E ^b   Bruce, M ^a   Barrett, D A ^a   Leong, C O ^a   Gaskell, M ^d   Wright, E K ^d   Farmer, P B ^d   Henderson, C J ^c   Wolf, R ^c   Stevens, M F G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c NINEWELLS HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Mice; Pharmacodynamic; Pharmacokinetic; Phortress; Rats; Toxicology

Indexed keywords

2 (4 AMINO 3 METHYLPHENYL) 5 FLUOROBENZOTHIAZOLE; 5 FLUORO 2 (4 LYSYLAMINO 3 METHYLPHENYL)BENZOTHIAZOLE; 5F 203; ALKALINE PHOSPHATASE; AMIDE; AMINE; ANTINEOPLASTIC AGENT; BENZENE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; BETA GALACTOSIDASE; CYTOCHROME P450 1A1; LYSINE DERIVATIVE; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; FLUORESCENCE; GENE; GENE INDUCTION; GENETIC TRANSCRIPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; MALE; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; RODENT; TRANSGENIC MOUSE; WEIGHT REDUCTION;

ALKALINE PHOSPHATASE; ANIMALS; BETA-GALACTOSIDASE; BODY WEIGHT; CYTOCHROME P-450 CYP1A1; DNA ADDUCTS; DRUG EVALUATION, PRECLINICAL; FEMALE; GENES, REPORTER; KIDNEY; LIVER; LUNG; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED ICR; ORGAN SIZE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLES;

EID: 57649091896     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000183846     Document Type: Article

References (21)

1. Bradshaw TD, Chua MS, Browne HL, Trapani V, Sausville EA, Stevens MFG: In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl) benzothiazoles. Br J Cancer 2002;86:1348-1354.
2. Bradshaw TD, Fichtner I, Bibby MJ, Double JA, Cooper PA, Alley MC, Tomaszewjski JE, Donahue S, Stinson SF, Sausville EA, Stevens MFG: Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl) benzothiazoles. Mol Cancer Ther 2002;1:239-246.
3. Loaiza-Pérez AI, Trapani V, Hose C, Singh SS, Trepel J, Stevens MFG, Bradshaw TD, Sausville EA: The AhR mediates sensitivity of MCF-7 breast cancer cells to the antitumour agent 2-(4-amino-3-methylphenyl) benzothiazole. Mol Pharmacol 2002;61:13-19.
4. Chua MS, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, Sausville EA, Stevens MFG: Role of CYP1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 2000;60:5196-5203.
5. Leong CO, Gaskell M, Martin EA, Heydon RT, Farmer PB, Bibby MC, Cooper PA, Double JA, Bradshaw TD, Stevens MFG: Antitumour 2-(4-aminophenyl) benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Br J Cancer 2003;88:470-477.
6. Newell DR, Burtles SS, Fox BW, Jodrell DI, Connors TA: Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics. Br J Cancer 1999;81:760-768.
7. Campbell SJ, Carlotti F, Hall PA, Clark AJ, Wolf CR: Regulation of the CYP1A1 promoter in transgenic mice: an exquisitely sensitive on-off system for cell specific gene regulation. J Cell Sci 1996;109:2619-2625.
8. Burtles SS, Newell DR, Henrar RE, Connors TA: Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. Eur J Cancer 1995;31A:408-410.
9. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
10. Phillips DH, Castegnaro M: Standardization and validation of DNA adduct postlabeling methods: report of the inter laboratory trials and production of recommended protocols. Mutagenesis 1999;14:301-315.
11. 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis 1986;7:1543-1551.
12. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A: Concordance of the toxicity of pharmaceuticals in humans and in animals. Reg Toxicol Pharmacol 2000;32:56-67.
13. Greaves P, Williams A, Eve M: First dose of potential new medicines to humans: how animals help. Nat Rev Drug Disc 2004;3:226-236.
14. Shimada T, Sugie A, Shindo M, Nakajima T, Azuma E, Hashimoto M, Inoue K: Tissue-specific indiction of cytochromes P450 1A1 and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in engineered C57BL/6J mice of aryhydrocarbon receptor gene. Toxicol Appl Pharmacol 2003;187:1-10.
15. Hose C, Holligshead M, Sausville EA, Monks A: Indiction of CYP1A1 in tumor cells by the antitumor agent 2-(4-amino-3-methylphenyl)-5- fluorobenzothiazole: a potential surrogate marker for patient sensitivity. Mol Cancer Ther 2003;2:1265-1272.
16. Bohr VA, Phillips DH, Hanawalt PC: Heterogenous DNA damage and repair in the mammalian genome. Cancer Res 1987;47:6426-6436.
17. Smart J, Daly AK: Variation in induced P4501A1 levels: relationship to P4501A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics 2000;10:11-24.
18. Larson-Su SA, Williams DE: Transplacental exposure to indole-3-carbinol induces sex-specific expression of CYP1A1 and CYP1B1 in the liver of Fischer neonatal rats. Toxicol Sci 2001;64:162-168.
19. Ma Q, Lu AY: Origins of individual variability in P4501A induction. Chem Res Toxicol 2003;16:249-260.
20. Denissenko MF, Pao A, Tang M, Pfeifer GP: Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996;274:430-432.
21. Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M, Pfeifer GP: Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 2000;92:803-811.